AstraZeneca Pharma India Limited

NSEI:ASTRAZEN Voorraadrapport

Marktkapitalisatie: ₹162.4b

AstraZeneca Pharma India Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Sanjeev Panchal

Algemeen directeur

₹38.7m

Totale compensatie

Percentage CEO-salaris83.4%
Dienstverband CEO1.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn1.3yrs
Gemiddelde ambtstermijn bestuurless than a year

Recente managementupdates

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Analyse CEO-vergoeding

Hoe is Sanjeev Panchal's beloning veranderd ten opzichte van AstraZeneca Pharma India's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹819m

Jun 30 2024n/an/a

₹959m

Mar 31 2024₹39m₹32m

₹2b

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹1b

Mar 31 2023₹21m₹5m

₹993m

Compensatie versus markt: De totale vergoeding ($USD 458.39K ) Sanjeev } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 481.78K ).

Compensatie versus inkomsten: De beloning van Sanjeev is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.


CEO

Sanjeev Panchal (47 yo)

1.8yrs

Tenure

₹38,725,314

Compensatie

Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mgeen gegevens
Bhavana Agrawal
Whole-Time Director & CFO1.1yrs₹30.59mgeen gegevens
Pratap Bhuvanagiri
Legal Counsel7.8yrs₹3.73mgeen gegevens
Manasa R.
Company Secretary & Compliance Officer2.3yrsgeen gegevensgeen gegevens
Smita Saha
Vice President of Human Resourcesno data₹12.28mgeen gegevens
Ayush Agarwal
Interim Business Unit Head of Oncology & Director of Commercial Excellence1.3yrsgeen gegevensgeen gegevens
Praveen Akkinepally
Head of Oncology Business Unitless than a yeargeen gegevensgeen gegevens
Vinay Sharma
Business Unit Head - Rare Disease unitless than a yeargeen gegevensgeen gegevens
Pankaj Jain
Legal Headno datageen gegevensgeen gegevens

1.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van ASTRAZEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mgeen gegevens
Bhavana Agrawal
Whole-Time Director & CFOless than a year₹30.59mgeen gegevens
Revathy Ashok
Independent Non-Executive Director7.9yrs₹1.20mgeen gegevens
Monica Widhani
Additional Independent Directorless than a yeargeen gegevensgeen gegevens
Hooi Chuah
Additional Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Nirula Shilpa Divekar
Independent Non-Executive Chairperson of the Board2.9yrs₹1.30mgeen gegevens
Sylvia Lorena Ramon
Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Jesus Javier Diaz Esteso
Additional Non-Executive Directorno datageen gegevensgeen gegevens

0.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ASTRAZEN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw bestuur.